Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
0(0%)
Results Posted
167%(5 trials)
Terminated
2(40%)

Phase Distribution

Ph phase_2
1
20%
Ph phase_3
4
80%

Phase Distribution

0

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
4(80.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(3)
Terminated(2)

Detailed Status

Completed3
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
60.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (20.0%)
Phase 34 (80.0%)

Trials by Status

terminated240%
completed360%

Recent Activity

0 active trials
Showing 5 of 5
terminatedphase_3

A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy

NCT04200352
completedphase_3

A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents

NCT03813238
completedphase_3

A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)

NCT03571256
terminatedphase_3

Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents

NCT03567291
completedphase_2

Alternatives for Reducing Tics in Tourette Syndrome (TS): A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents

NCT03452943

Clinical Trials (5)

Showing 5 of 5 trials
NCT04200352Phase 3

A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy

Terminated
NCT03813238Phase 3

A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents

Completed
NCT03571256Phase 3

A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)

Completed
NCT03567291Phase 3

Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents

Terminated
NCT03452943Phase 2

Alternatives for Reducing Tics in Tourette Syndrome (TS): A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5